Bioforce Nanosciences Hldgs In Financials
This page shows Bioforce Nanosciences Hldgs In (BFNH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Balance-sheet repair came from liabilities shrinking, while the company still operated with an almost nonexistent asset base.
Between FY2024 and FY2025, liabilities fell from$2.3M to$619K , which is the main reason the balance sheet looks less strained. Assets did not recover with it: year-end assets were only$786 and the current ratio was 0.0013x, so the improvement reflects smaller claims, not a rebuilt operating base.
Shares outstanding rose to 33.5M from 29.3M across the last year shown. Yet cash and total assets were still under
Some figures from recent filings were inconsistent and were omitted from this summary.
Financial Health Signals
Bioforce Nanosciences Hldgs In does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
Bioforce Nanosciences Hldgs In earned -$0.04 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Bioforce Nanosciences Hldgs In held $786 in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
None of these metrics is reported for fiscal year 2025.
Capital Allocation
None of these metrics is reported for fiscal year 2025.
BFNH Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | $18K+9.0% | $16K+262.4% | $5K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | $13K+15.2% | $12K+258.9% | $3K |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | $4K-6.5% | $5K+271.7% | $1K |
| SG&A Expenses | N/A | N/A | N/A | N/A | N/A | $81K+59.2% | $51K-28.7% | $71K+119.6% | $33K |
| Operating Income | N/A | N/A | N/A | N/A | N/A | N/A | -$47K+30.3% | -$67K-113.5% | -$31K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0 | N/A |
| Net Income | N/A | N/A | N/A | N/A | N/A | N/A | -$47K+31.3% | -$68K-116.7% | -$31K |
| EPS (Diluted) | -$0.04-100.0% | -$0.020.0% | -$0.020.0% | -$0.02 | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: R&D Expenses, Interest Expense.
BFNH Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $786-8.8% | $862+35.1% | $638-13.1% | $734-93.4% | $11K-72.0% | $40K-32.3% | $59K+67.7% | $35K+68.0% | $21K |
| Current Assets | $786-8.8% | $862+35.1% | $638-13.1% | $734-93.4% | $11K-72.0% | $40K-32.3% | $59K+67.7% | $35K+68.0% | $21K |
| Cash & Equivalents | $786-8.8% | $862+35.1% | $638-13.1% | $734-93.4% | $11K-72.1% | $40K-24.6% | $53K+80.0% | $29K+105.2% | $14K |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $6K+27.4% | $5K |
| Total Liabilities | $619K-73.1% | $2.3M+26.5% | $1.8M+35.0% | $1.3M+54.4% | $873K+118.4% | $400K+3350.2% | $12K+117.7% | $5K-58.1% | $13K |
| Current Liabilities | $619K-73.1% | $2.3M+26.5% | $1.8M+35.0% | $1.3M+54.4% | $873K+118.4% | $400K+3350.2% | $12K+117.7% | $5K-58.1% | $13K |
| Total Equity | -$619K+73.1% | -$2.3M-26.5% | -$1.8M-35.0% | -$1.3M-56.3% | -$862K-139.5% | -$360K-860.8% | $47K+58.7% | $30K+263.4% | $8K |
| Retained Earnings | -$162.4M-0.8% | -$161.1M-0.3% | -$160.6M-0.3% | -$160.2M-0.3% | -$159.7M-0.3% | -$159.2M-20795.3% | -$762K-6.5% | -$715K-10.5% | -$647K |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
BFNH Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | N/A | N/A | N/A | N/A | N/A | -$80K-228.9% | -$24K+61.0% | -$62K-141.2% | -$26K |
| Financing Cash Flow | N/A | N/A | N/A | N/A | $49K-27.0% | $67K+40.3% | $48K | N/A | N/A |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
BFNH Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | 24.5%-4.1pp | 28.6%+0.7pp | 27.9% |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | -261.8% | -409.2% | -694.7% |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | -261.8% | -415.3% | -694.7% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | -98.4%+128.9pp | -227.3%+153.9pp | -381.1% |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | -79.0%+113.8pp | -192.8%-43.3pp | -149.5% |
| Current Ratio | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.01-0.1x | 0.10-5.0x | 5.08-1.5x | 6.60+5.0x | 1.65 |
| Debt-to-Equity | N/A | N/A | N/A | N/A | N/A | N/A | 0.24+0.1x | 0.18-1.4x | 1.55 |
Not reported in any period shown, so not listed: FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Note: Shareholder equity is negative (-$619K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Where Bioforce Nanosciences Hldgs In Ranks
Frequently Asked Questions
What are Bioforce Nanosciences Hldgs In's total assets?
Bioforce Nanosciences Hldgs In (BFNH) had $786 in total assets as of fiscal year 2025, including both current and long-term assets.
What is Bioforce Nanosciences Hldgs In's current ratio?
Bioforce Nanosciences Hldgs In (BFNH) had a current ratio of 0.00 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
Why is Bioforce Nanosciences Hldgs In's debt-to-equity ratio negative or not reported?
Bioforce Nanosciences Hldgs In (BFNH) has negative shareholder equity of -$619K as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.